There have been 91 cases of measles in the last week and a half, bringing the number of cases so far this year to 971; a coalition of civil rights group is suing the Trump administration over the recently issued conscience protection rule; Oklahoma's opioid trial against Johnson & Johnson has started.
The number of measles cases in the United States has reached 971, including 91 in the past week and a half, according to the CDC. Just 5 months into the year, this is the greatest number of cases reported since 1992, when 963 cases were reported for the entire year. The CDC said it continues to work with affected state and local health departments to get control of ongoing outbreaks, including those in New York City and Rockland County, New York, which have continued for nearly 8 months. According to the CDC, if these 2 outbreaks continue through summer and fall, the United States may lose its measles elimination status.A group of civil rights groups have filed a lawsuit against the Trump administration, arguing that the recently issued conscience protection rule that allows healthcare providers to refuse to provide care if it goes against their religious beliefs is unconstitutional. The coalition, which includes Lambda Legal and the Center for Reproductive Rights, said that the rule will cause “mass confusion among healthcare providers and is completely infeasible to implement.” According to The Hill, they also argue that healthcare providers may scrap reproductive and LGBTQ services as a whole, leaving millions without care.Oklahoma’s opioid trial against Johnson & Johnson has started, with Oklahoma Attorney General Mike Hunter telling a judge that the drug company’s greed for more sales fueled the opioid epidemic in the state, and that the company should pay billions of dollars as compensation. The attorney general added that Johnson & Johnson used a “deceitful, multibillion-dollar brainwashing campaign” to dupe doctors into prescribing opioids for unapproved ailments, reported Bloomberg. Oklahoma’s lawsuit is 1 of more than 1600 filed and the first to go to trial.
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More